Human Regenerative Technologies (HRT) Announces Successful One Year Anniversary of Industry's First Room Temperature Pre-Mixed Flowable Placental Tissue Matrix

Share Article

HRT’s advanced HydraTek® process has produced an extensive allograft product offering, including a variety of amniotic membrane configurations, a cryo-preserved flowable placental tissue matrix and the world’s first ambient temperature flowable placental tissue matrix. This patent-pending formulation is the only one of its kind in market, and offers physicians and facilities an off-the-shelf, ready-to-use, viable connective tissue matrix, designed for efficient and precise delivery to the intended site.

News Image
HRT amniotic and placental biologics are demonstrating to be an ideal solution for the treatment of many wounds and surgical challenges,” commented Chris Sharp, CEO “We have developed the industry’s most diverse line of active amniotic biologics"

REDONDO BEACH, CA (May 13th, 2015) – Human Regenerative Technologies, LLC (HRT®) is a regenerative biologics company, focused on advancing the understanding and development of human cellular and protein-based therapies through scientific and clinical application.

HRT's commercially available regenerative biologics successfully combines precise science and technology in the procurement, processing and delivery of innovative and novel active Extracellular Matrix (ECM) biologic products derived from human amniotic and placental tissues.

HRT’s advanced HydraTek® process has produced an extensive allograft product offering, including a variety of amniotic membrane configurations, a cryo-preserved flowable placental tissue matrix and the world’s first ambient temperature flowable placental tissue matrix. This patent-pending formulation is the only one of its kind in market, and offers physicians and facilities an off-the-shelf, ready-to-use, viable connective tissue matrix, designed for efficient and precise delivery to the intended site.

HRT is continuing to lead in the advancement and development of novel next-generation amniotic and placental tissue matrix products such as our AmnioPro®45 Membrane, AmnioPro®200 Membrane, AmnioPro®-A Tissue Matrix, and AmnioPro®-C Tissue Matrix, part of a complete portfolio of advanced biologics for many surgical and in-office medical specialties.

HRT continues to expand its national and international distribution network and private label opportunities with synergistic medical companies.

“HRT amniotic and placental biologics are demonstrating to be an ideal solution for the treatment of many wounds and surgical challenges,” commented Chris Sharp, CEO “We have developed the industry’s most diverse line of active amniotic biologics utilizing our proprietary HydraTek™ process, and are thrilled to be sharing them with Wound Care, Foot & Ankle, Urology, Podiatry, OB/GYN, ENT, Dental, Oral and Maxillofacial, Orthopedics, Spine, Plastics and Cosmetics communities through our various distribution channels. Our mission continues to be advancing our novel line of placental tissue-based products with the goal of enhancing the quality of patient care in a broad range of clinical applications.”

About Human Regenerative Technologies LLC (HRT) Harnessing the Regenerative Power of the Body®:

For more information, visit our website at http://www.humantissue.com or email: info(at)humantissue(dot)com

Forward-looking statement
Any forward-looking statement is based on information available to Human Regenerative Technologies LLC as of the date of the statement. All written or oral forward-looking statements attributable to Human Regenerative Technologies LLC are qualified by this caution. HRT does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in HRT’s expectations.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Visit website